Edwards Lifesciences Corporation (EW) has drawn significant interest with multiple transactions in its shares. Munich Reinsurance Co Stock Corp, Universal Beteiligungs und Servicegesellschaft mbH, Zurcher Kantonalbank Zurich Cantonalbank, TriaGen Wealth Management, Mirae Asset Global Investments, Lecap Asset Management, Ninety One SA Pty and Lbp Am Sa have all added significant holdings in EW. Recent earning results revealed that the company surpassed expectations for Q1 2026, leading to a buoyant stock performance. The earnings beat led to an increased revenue outlook for 2026. Sharp gains in heart valve devices have boosted EW's stock while the firm announced a $500M accelerated share buyback. Despite some shares sold by entities like OLD National Bancorp IN, Birch Hill Investment Advisors and KBC Group NV, and the sale of 22,680 shares by a company VP, the overall sentiment remains largely positive. The corporation's Q4 2025 EPS miss resulted in a share climb, demonstrating positive investor sentiment. The consensus among analysts is moderate buy with a target price range of $85 to $110. Earnings potential remains strong and many analysts continue bullish on EW stock.
Edwards Lifesciences Corp EW News Analytics from Wed, 13 Aug 2025 07:00:00 GMT to Sat, 25 Apr 2026 23:14:23 GMT -
Rating 8
- Innovation 6
- Information 9
- Rumor 3
